Form 4: Viatris Inc. Executive Ni Xiangyang (Sean) Reports Stock Transactions
SEC Form 4
Ni Xiangyang (Sean), President, Greater China at Viatris Inc., reports acquisition and disposition of VTRS common stock and derivative securities related to vesting of restricted stock units and performance restricted stock units.
Summary
- On March 2, 2024, Ni Xiangyang acquired 17,011 shares of Viatris common stock through the vesting of Performance Restricted Stock Units (PRSUs) and 7,195 shares through Restricted Stock Units (RSUs).
- An additional 952 shares were acquired through Dividend Equivalent Units (DEUs) related to RSUs on the same date.
- On March 3, 2024, 13,627 shares were acquired through vesting of RSUs and 671 shares through related DEUs.
- On March 4, 2024, 7,564 shares were acquired through vesting of RSUs and 658 shares through related DEUs.
- On March 4, 2024, Ni Xiangyang disposed of 17,755 shares at a weighted average price of $12.5394 and 3,777 shares at a weighted average price of $12.3582 to cover tax liabilities associated with vesting.
- Following these transactions, Ni Xiangyang directly owns 90,804 shares of Viatris common stock.
Sentiment
Score: 6
Explanation: The document reflects routine executive compensation activity. The vesting of shares is a positive sign, but the sale to cover taxes is neutral. Overall, the sentiment is slightly positive.
Positives
- The vesting of restricted stock units indicates that the executive is meeting performance or time-based milestones set by the company.
Negatives
- The sale of shares to cover tax liabilities, while common, could be interpreted as a lack of confidence in the company's short-term prospects, although it is a standard practice.
Risks
- Executive stock sales could create short-term downward pressure on the stock price.
Industry Context
Executive stock transactions are a normal part of corporate governance and compensation practices. Monitoring these transactions can provide insights into management's perspective on the company's performance and future prospects.
Comparison to Industry Standards
- Executive compensation packages including stock options and restricted stock units are common across the pharmaceutical industry.
- Companies like Teva Pharmaceutical Industries and Novartis also utilize similar equity-based compensation to align executive interests with shareholder value.
- The vesting schedules and performance metrics associated with these grants vary depending on the company's specific goals and compensation philosophy.
Stakeholder Impact
- The transactions have a minor impact on shareholders due to the small volume of shares involved relative to the company's total outstanding shares.
- Employees may be affected by the perceived sentiment of the executive's actions.
Key Dates
| Date | Description |
|---|---|
| 03/02/2021 | Initial grant date of Performance Restricted Stock Units (PRSUs). |
| 03/02/2021 | Grant date of Restricted Stock Units (RSUs). |
| 03/02/2022 | Vesting date of 7,195 RSUs granted on March 2, 2021. |
| 03/03/2023 | Grant date of Restricted Stock Units (RSUs). |
| 03/04/2022 | Grant date of Restricted Stock Units (RSUs). |
| 03/04/2023 | Vesting date of 7,563 RSUs granted on March 4, 2022. |
| 03/02/2024 | Vesting date of PRSUs granted on March 2, 2021. |
| 03/02/2024 | Vesting date of 7,195 RSUs granted on March 2, 2021. |
| 03/02/2024 | Transaction date for acquisition of shares through vesting of PRSUs and RSUs. |
| 03/03/2024 | Transaction date for acquisition of shares through vesting of RSUs. |
| 03/03/2024 | Vesting date of 13,627 RSUs granted on March 3, 2023. |
| 03/04/2024 | Transaction date for acquisition and disposition of shares. |
| 03/04/2024 | Vesting date of 7,564 RSUs granted on March 4, 2022. |
| 03/04/2024 | Grant date of Restricted Stock Units (RSUs). |
| 03/05/2024 | Date of Form 4 filing. |
| 03/03/2025 | Future vesting date of 13,627 RSUs granted on March 3, 2023. |
| 03/04/2025 | Future vesting date of 7,564 RSUs granted on March 4, 2022. |
| 03/04/2025 | Future vesting date of 12,649 RSUs granted on March 4, 2024. |
| 03/03/2026 | Future vesting date of 13,627 RSUs granted on March 3, 2023. |
| 03/04/2026 | Future vesting date of 12,648 RSUs granted on March 4, 2024. |
| 03/04/2027 | Future vesting date of 12,648 RSUs granted on March 4, 2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.